For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG is committed to the evaluation of innovative cell therapy products, strategies to improve cell therapy outcomes and to advancing accessibility for Canadian patients.
“The exciting launch of these first two trials involving cell therapies is the result of years of work and investment by many,” says Dr. Annette Hay, CCTG Senior Investigator. “We are excited to deliver on the strong foundation that has been built, to complete these studies, and develop new trials as we continue to work towards improved outcomes for Canadians with cancer.”
A new clinical trial has opened in Canada for patients with peripheral T-cell lymphoma (PTCL), investigating whether an intensive treatment approach can reduce the risk of the disease returning after initial chemotherapy.
“This is a clinical trial that CCTG and other cooperative groups are uniquely positioned to undertake in order to improve the lives of patients; For-profit organizations will not do this for patients,” Dr. Neil Sun Chua, LYC2 study chair and Medical Oncologist at the Cross Cancer Institute.
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the topic of Compliance Tips and CAPA Tricks.
The Rave EDC 2026.2.0 release will be deployed on June 29 and includes a refreshed user interface (UI) designed to enhance the user experience. This update applies only to studies within the CCTG2 study group and will not affect studies outside of this group. We anticipate no downtime during this upgrade.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
CCTG would like to welcome Melanie Keats as the new patient representative supporting the Gynecologic Disease Site Committee. Melanie resides in Halifax Nova Scotia and is a a Professor and Associate Research Scholar, Health Populations Research Institute at Dalhousie University as well as a Nova Scotia Health Authority Affiliated Scientist and Co-Director Physical Activity and Cancer (PAC) Lab.
